CA-DEBIOPHARM
9.1.2024 15:01:34 CET | Business Wire | Press release
MedaSystems, a pioneer in software to provide access to pre-approval medicine, is pleased to announce additional funding from Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, motivated by their vision of patient centric, data-enabled clinical research and enabling patients to access novel treatments sooner. The investment adds to a growing list of prominent digital health investors in Europe and the United States, including Nina Capital and Young Sohn, a co-founder of Veeva Systems. The funding speaks to the global nature of pre-approval access and its increasing importance in the drug development process.
“We see significant synergies between MedaSystems and Debiopharm Innovation Fund. Our mutual dedication to building new approaches to pharmaceutical drug development and patient care will help bring promising pre-approval medicine to patients around the world, faster and more equitably. This funding supports our goal of making life-saving treatments more easily available to patients and physicians while advancing research and development of new therapies,” said Fiona Smythe, CEO of MedaSystems.
MedaSystems' SaaS platform facilitates the rapid processing of treatment inquiries and introduces new data capture capabilities, streamlining treatment for patients with unmet medical needs and aiding in collecting real-world data (RWD) for regulatory submissions. The platform is a vital link that ensures smooth collaboration among key partners in situations requiring pre-approval access. Physicians can swiftly manage patient requests and oversee the entire process in-app, working seamlessly with their teams and pharmacists. Pharmaceutical companies can integrate external partners like contract research organizations (CROs), guaranteeing effective communication, integrated services, and the quick shipment of treatment.
"Debiopharm Innovation Fund is committed to breaking down barriers in healthcare and promoting patient-centered solutions. Our investment in MedaSystems aligns perfectly with our dedication to innovation and the power of digital health technology in transforming patient outcomes. We believe their visionary approach to simplifying pre-approval access will play a key role in accelerating the delivery of life-saving treatments around the world. Together, we look forward to crafting a future where every patient has timely access to the most promising therapies." said Vincent Lepreux, Investment Principal at Debiopharm Innovation Fund.
About MedaSystems
MedaSystems is the leading developer of software that streamlines the handling of requests for experimental therapies from healthcare providers, supporting both Expanded Access and Post-Trial Access. MedaSystems' secure and GxP compliant application acts as a centralized environment, connecting physicians and pharmaceutical companies to facilitate global patient access to investigational therapies. By enabling the tracking and management of inquiries and data collection from these programs, MedaSystems transforms communications with clinicians into true partnerships, significantly reducing time and frustration for both parties involved.
About Debiopharm Innovation Fund
Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, provides funding and guidance for companies with an ambition to improve the patient journey and transform pharmaceutical R&D. Since 2017, Debiopharm has invested in 15 AI and digital health companies, typically leading the investment rounds. As of September 2023, Debiopharm Innovation Fund is expanding its footprint through a new Seed financing activity.
For more information, please visit www.debiopharm.com/innovation-fund/
To learn more about investment criteria visit https://www.debiopharm.com/innovation-fund/approach/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240109101056/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sparxity Appoints former Cray CEO Peter Ungaro and Semiconductor Veteran Daniel Armbrust to its Advisory Board17.11.2026 16:00:00 CET | Press release
Appointments bring decades of leadership experience in supercomputing, semiconductor commercialization, and scaling advanced computing business Sparxity, a leader in sparse-native computing, today announced that Peter Ungaro, former President and CEO of Cray, Inc., and Daniel Armbrust, former President and CEO of SEMATECH and co-founder of Silicon Catalyst, have joined its Advisory Board as independent members. Armbrust has been elected Chairman of the Advisory Board and Ungaro Deputy Chairman by their fellow board members. The appointments strengthen the company’s leadership as it scales its sparse-native computing technology for next-generation AI and high-performance computing (HPC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117761685/en/ From left to right, Daniel Armbrust, former President and CEO of SEMATECH and co-founder of Silicon Catalyst and Peter Ungaro, former President and CEO of Cray, Inc. Peter Ungaro
SES to Develop European Direct-to-Device Technologies under ESA Partnership Project17.11.2026 15:30:00 CET | Press release
The new SELYCE programme supports transition towards hybrid networks to strengthen Europe’s critical communications infrastructures SES today announced it will lead the industrial activities of SELYCE, a new European initiative focused on developing the technologies needed to enable future Direct-to-Device (D2D) satellite services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117544892/en/ SES to Develop European Direct-to-Device Technologies under ESA Partnership Project Conducted under a Partnership Project with the European Space Agency (ESA) and supported by the Luxembourg Space Agency (LSA), Belgian Science Policy Office (BELSPO) and UK Space Agency (UKSA), SELYCE brings together European industry and research organisations to advance standards-based 5G Non-Terrestrial Network (NTN) capabilities that will allow everyday smartphones and IoT devices to connect seamlessly via satellite beyond the reach of terrestrial
From returns to restaurant bookings: Klarna’s AI assistant finds the best product & price, buys it for you, and you don’t pay until it arrives17.11.2026 15:26:00 CET | Press release
The Klarna AI-assistant takes the admin off your hands, on WhatsApp and iMessage. Waitlist opens today Klarna, the everyday finance network, today announced the Klarna AI-assistant, a personal assistant that handles shopping, returns, bookings, and everyday admin, so you don’t have to. Currently live with a small group of early users, the AI-assistant acts like a personal concierge, handling tasks on each customer’s behalf while keeping them firmly in control. Waitlist opens this week. The Klarna AI-assistant finds options and helps people decide, books anything from a table for two, to a babysitter, and keeps track of what they’re waiting for. It drafts email replies for approval, files receipts, and flags upcoming birthdays with gift ideas. This new AI-assistant builds on Klarna’s shopping assistant, a popular feature in its app. Klarna customers have spent more than $34 billion through the app’s built-in browser since 2020, a feature that lets you shop any website, including stores
Impartner Launches MCP Server to Connect AI Assistants with Live PRM Data17.11.2026 15:19:00 CET | Press release
Impartner MCP gives partner program teams conversational access to live partner pipeline, deal registration and account data through supported AI assistants, while maintaining existing user permissions and data access controls. Impartner, the world's leading partner revenue orchestration platform, today announced the launch of Impartner MCP, enabling organizations to connect AI assistants directly to live partner relationship management (PRM) data. Powered by the Model Context Protocol (MCP), an open standard for connecting AI assistants with external systems and data sources, the integration makes Impartner PRM information accessible within supported AI environments without requiring users to navigate multiple reports and dashboards. With Impartner MCP, teams can ask natural-language questions about partner pipelines, deal registrations, account activity and program performance, receiving answers grounded in real-time operational data and governed by their existing access permissions.
Incode Launches Incode Know Your Agent to Anchor AI Agent Trust in Verified Human Identity17.11.2026 15:14:00 CET | Press release
Businesses can now verify the human behind every AI agent acting on behalf of their customers and get access, control, and visibility over everything it does Incode, the identity platform trusted by more than 800 organizations, including nine of the top 10 US banks, eight of the top nine US telcos, and four of the top five global marketplaces, today launched Incode Know Your Agent, which ties every AI agent to a verified person and to the mandate that person set. With Incode Know Your Agent, businesses can get access, control, and visibility over every agent that acts on behalf of their customers. AI agents already act on behalf of people in banking, commerce, and everyday services. A fraudster’s agent can arrive with the same valid credentials as a customer’s, making it impossible for a business to tell them apart. AI agents are creating a new kind of economy, and fraud is growing inside it. Nearly seven in 10 Americans (69%) say they would let a bank’s AI assistant complete at least
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
